Detection method for treating inflammatory bowel disease through macrophage migration inhibitory factor resistant antibody

Abstract

The invention belongs to the technical field of bowel disease detection and discloses a detection method for treating an inflammatory bowel disease through a macrophage migration inhibitory factor resistant antibody. The method includes experimental animals and grouping, model establishing and drug interference, specimen collection and treatment, and statistical analysis. Blocking of TLR4 / NF-kB signal channel excessive activation is achieved through the MIF resistant monoclonal antibody for the first time, the influence, on downstream proinflammatory factors such as MIF, NF-kB, TNF-alpha, IL-6, of blocking resistance and the MIF resistant monoclonal antibody is analyzed deeply, and the blocking effect of the MIF resistant monoclonal antibody and the protective effect on ulcerative colitis(UC) are determined; and by starting from the micro level of a cell factor grid system in UC, and the pivotal role of the NF-kB factor in UC inflammatory factors and the association of the NF-kB factor with the MIF, TNF-alpha and IL-6 are determined.

Description

technical field [0001] The invention belongs to the technical field of intestinal disease detection, and in particular relates to a detection method for treating inflammatory bowel disease with an anti-macrophage migration inhibitory factor antibody. Background technique [0002] At present, the existing technologies commonly used in the industry are as follows: [0003] IBD is a chronic non-specific inflammatory disease of the intestine, including ulcerative colitis (UC) and Crohn's disease (CD). To clarify, there are no sensitive diagnostic indicators and effective treatment measures. In recent years, studies at home and abroad believe that the imbalance between pro-inflammatory and anti-inflammatory factors is an important link in the pathogenesis of IBD. MIF is an important pro-inflammatory cytokine that participates in the pathogenesis of IBD and is related to disease activity. Antibodies against MIF may open up a new avenue for the treatment of IBD. In IBD, the proc...

AI Technical Summary

Problems solved by technology

MIF was first discovered in the delayed immune response. It is an important pro-inflammatory cytokine and plays a vital role in regulating immune and inflammatory responses. At present, MIF is mainly used in autoimmune diseases and inflammation in China. There is still a lack of clinical research data for basic research on diseases, cancer, transplant rejection, etc. At the same time, there are few research reports on MIF in the occurrence and development of IBD diseases. Anti-MIF antibodies mainly reduce the infiltration of macrophages by blocking the expression of MIF However, the anti-MIF antibody is expensive. At present, there are mainly research reports on the antibody in liver cancer, colorectal cancer, breast cancer and other diseases in China, and it is suggested that anti-MIF antibody can down-regulate vascular endothelial growth factor, reduce microvascular density, etc. However, except for the articles published by our research group, there is no report on the basic or clinical application of anti-MIF antibodies in IBD in China; although there are studies on the relationship between MIF and IBD in foreign countries, it is also proposed that MIF Potential role in the treatment of IBD, but there is a lack of reports on the application and therapeutic efficacy of anti-MIF antibodies in this disease. Therefore, our basic research on the therapeutic effects of anti-MIF antibodies in IBD not only verified the role of MIF in IBD The important role in the pathogenesis of the disease has also verified the therapeutic effect of anti-MIF antibodies in this disease, and may become the theoretical basis and research cornerstone of anti-MIF antibodies for clinical disease treatment

[0006] To sum up, the problems existing in the prior art are: currently, anti-TNF-α antibody and anti-IL-6 antibody have been successfully applied clinically to treat CD, but the curative effect of anti-MIF antibody on IBD has not been reported in China, and foreign rare reports

[0008] Difficulty: Although the present invention affirms the curative effect of anti-MIF antibody on IBD to a certain extent, it still needs to determine the use of the antibody because it is only a basic research and stays at the level of animal research, lack of clinical basis, and there are risks such as immune rejection. Security and Stability

Images